Authors:
Scotton, PG
Pea, F
Giobbia, M
Baraldo, M
Vaglia, A
Furlanut, M
Citation: Pg. Scotton et al., Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis, CLIN INF D, 33(9), 2001, pp. E109-E111
Citation: M. Baraldo et al., Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients, PHARMAC RES, 43(6), 2001, pp. 547-551
Citation: F. Pea et M. Furlanut, Pharmacokinetic aspects of treating infections in the intensive care unit - Focus on drug interactions, CLIN PHARMA, 40(11), 2001, pp. 833-868
Authors:
Brusaferro, S
Rinaldi, O
Pea, F
Faruzzo, A
Barbone, F
Citation: S. Brusaferro et al., Protocol implementation in hospital infection control practice: an Italianexperience of preoperative antibiotic prophylaxis, J HOSP INF, 47(4), 2001, pp. 288-293
Authors:
Pea, F
Brollo, L
Lugano, M
Dal Pos, L
Furlanut, M
Citation: F. Pea et al., Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuousvenovenous hemofiltration, THER DRUG M, 23(5), 2001, pp. 587-588
Citation: F. Pea et al., Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function - Multiple daily doses may be preferable, CLIN DRUG I, 19(3), 2000, pp. 213-218
Citation: F. Pea et al., High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures, J ANTIMICRO, 45(3), 2000, pp. 329-335
Authors:
Pea, F
Milaneschi, R
Baraldo, M
Lugatti, E
Talmassons, G
Furlanut, M
Citation: F. Pea et al., Ciprofloxacin disposition in elderly patients with LRTI being treated withsequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): Comparative pharmacokinetics and the role of therapeuticdrug monitoring, THER DRUG M, 22(4), 2000, pp. 386-391
Citation: F. Pea et al., Systemic vancomycin overexposure in a patient with spinal cord injury who had staphylococcal sepsis and Clostridium difficile colitis, THER DRUG M, 22(2), 2000, pp. 233-234
Citation: F. Pea et al., Pharmacokinetic profile of two different administration schemes of teicoplanin - Single 400mg intravenous dose vs double-refracted 200mg intramuscular doses in healthy volunteers, CLIN DRUG I, 18(1), 1999, pp. 47-55
Authors:
Baraldo, M
Ferraccioli, G
Pea, F
Gremese, E
Furlanut, M
Citation: M. Baraldo et al., Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy, PHARMAC RES, 40(6), 1999, pp. 483-486
Authors:
Pea, F
Damiani, D
Michieli, M
Ermacora, A
Baraldo, M
Russo, D
Fanin, R
Baccarani, M
Furlanut, M
Citation: F. Pea et al., Multidrug resistance modulation in vivo: The effect of cyclosporin A aloneor with dexverapamil on idarubicin pharmacokinetics in acute leukemia, EUR J CL PH, 55(5), 1999, pp. 361-368
Citation: G. Wu et al., Effect of the number of samples on Bayesian and non-linear least-squares individualization: A study of cyclosporin treatment of haematological patients with multidrug resistance, J PHARM PHA, 50(3), 1998, pp. 343-349